About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: BCRX
- CUSIP: 09058V10
- Previous Close: $6.12
- 50 Day Moving Average: $6.17
- 200 Day Moving Average: $5.19
- 52-Week Range: $1.74 - $7.56
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.01
- P/E Growth: -0.36
- Market Cap: $451.40M
- Outstanding Shares: 73,758,000
- Beta: 3.67
- Net Margins: -313.02%
- Return on Equity: -296.19%
- Return on Assets: -68.58%
Companies Related to BioCryst Pharmaceuticals:
- Debt-to-Equity Ratio: 6.35%
- Current Ratio: 1.25%
- Quick Ratio: 1.21%
What is BioCryst Pharmaceuticals' stock symbol?
BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."
Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?
8 equities research analysts have issued 12 month target prices for BioCryst Pharmaceuticals' stock. Their predictions range from $3.00 to $11.00. On average, they expect BioCryst Pharmaceuticals' stock price to reach $8.00 in the next twelve months.
When will BioCryst Pharmaceuticals announce their earnings?
BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
Who owns BioCryst Pharmaceuticals stock?
BioCryst Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include RTW Investments LP (5.53%), Deerfield Management Co. (4.39%), State Street Corp (2.84%), Perceptive Advisors LLC (1.80%), FMR LLC (1.00%) and Royce & Associates LP (0.20%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Jon P Stonehouse, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu.
Who sold BioCryst Pharmaceuticals stock? Who is selling BioCryst Pharmaceuticals stock?
BioCryst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Co., RTW Investments LP, Royce & Associates LP, Metropolitan Life Insurance Co. NY and National Planning Corp. Company insiders that have sold BioCryst Pharmaceuticals stock in the last year include Alane P Barnes, Bros Advisors Lp Baker, Thomas R Staab II and Yarlagadda S Babu.
Who bought BioCryst Pharmaceuticals stock? Who is buying BioCryst Pharmaceuticals stock?
BioCryst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, State Street Corp, FMR LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Trexquant Investment LP, Ellington Management Group LLC and Federated Investors Inc. PA.
How do I buy BioCryst Pharmaceuticals stock?
Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BioCryst Pharmaceuticals stock cost?
One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $6.10.